Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Film Coated Tablets 60 x 20 mg |
|
||
|
Film Coated Tablets 60 x 50 mg |
|
||
|
Film Coated Tablets 60 x 70 mg |
|
||
|
Film Coated Tablets 30 x 100 mg |
|
Dosage
Therapy should be initiated by a physician experienced in the diagnosis and treatment of patients with leukaemia.
The recommended dose for chronic phase CML is 100 mg dasatinib once daily.
The recommended dose for accelerated, myeloid or lymphoid blast phase (advanced phase) CML or Ph+ ALL is 140 mg once daily.
Administer orally, with or without a meal. Do not crush, cut, or chew tablets.
Please refer to the patient leaflet for the complete information.
Indications
Treatment of adult patients with:
• Newly diagnosed Philadelphia chromosome positive (Ph+) chronic
myelogenous leukaemia (CML) in the chronic phase.
• Chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate.
• Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with
resistance or intolerance to prior therapy.
Contra-Indications
Hypersensitivity to the active substance or to any of the excipients.
Special Precautions
Please refer to the patient leaflet for the complete information.
Side Effects
Please refer to the patient leaflet for the complete information.
Drug interactions
Please refer to the patient leaflet for the complete information.
Pregnancy and Lactation
Please refer to the patient leaflet for the complete information.
Overdose
Please refer to the patient leaflet for the complete information.
